品系特征：

• CD28的胞外结构域完全被人源化；
• hCD28的表达模式及调控是生理性的；
• 健全的鼠源免疫系统；
• mCD28（胞外区）不表达，可避免交叉反应；

验证信息：

（1）hCD28在T细胞上的表达情况

从WT和hCD28小鼠上分离脾细胞；

• hCD28小鼠上，hCD28在CD8+、CD4+T以及Treg细胞上的表达情况与WT小鼠类似；

（2）hCD28 靶点功能检测

从WT和hCD28小鼠上分离 T 细胞，加入αCD3和α-mCD28或α-hCD28共孵育4天后检测；

• αCD3和αCD28共刺激诱导小鼠T细胞表达CD25（T细胞活化标志物），同时促进T细胞增殖；
• 该模型的hCD28是有功能的。

更多详细数据请联系我们：联系我们 - 基锘威 - genOway (my3w.com)

案例

1. Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015
2. Uncoupling efficacy from toxicity: a case study on MEDI5752

评论

1. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
2. A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway
3. An alternative approach to immunotherapy: A bispecific agonist 
4. Relevant preclinical models to test T-cell engagers: The case of CD28 
5. Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies 
6. Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies
7. A VISTA on naive T cell fate 
8. A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies 
9. Immune checkpoint inhibitors: A strategy to tackle cancer? 

海报

1. Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies